Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population

Summary

The objective of this retrospective study was to evaluate the potential ability of diluted Russell viper-venom time (dRVVT) to identify antiphospholipid syndrome (APS) in a lupus anticoagulant (LA)-positive patient population, already selected by other LA clotting tests. Our cohort of positive LA patients was first identified in our outpatients population by the following sensitive LA-detecting tests: Rosner index, diluted prothrombin time (dPT) and Rosove index. Then the 227 consecutive LA-positive patients were tested for dRVVT with the same blood sample. Anticardiolipin (aCL) and anti-β2-glycoprotein-I (β2GPI) autoantibodies assays were also performed. APS using Sapporo clinical criteria revised at Sydney, was found in 116 of these 227 consecutive LA-positive patients. Results of the different tests were analysed statistically. Using univariate analysis, dRVVT, dPT, IgG aCL and IgG anti-β2GPI autoantibodies were significantly associated with APS. The receiver operating-characteristics (ROC) curve defined the best cut-off value for dRVVT ratio at 1.61 with a good specificity (78%) and a lower sensitivity (53%). A multivariate analysis using a binary logistic procedure, retained the dRVVT ratio (≥ 1.61) and IgG anti-β2GPI autoantibodies (> 15 USG) as being associated with APS (p = 0.018; odds ratio [OR] 2.39; 95% confidence interval [CI] 1.2–4.7, and p = 0.0001; OR 3.2; 95% CI 1.5–6.5, respectively). To conclude, these results agree with the need for LA criteria favouring specificity over sensitivity. The use of a threshold around 1.6 for dRVVT ratio should help discriminate APS from non-APS patients.

Keywords

Antiphospholipid autoantibodies - diluted viper venom time

• References

• 1 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
• 2 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
• 3 Petri M. Epidemiology of the antiphospholipid syndrome. J Autoimmun 2000; 15: 145-151.
• 4 Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiol 2003; 207: 5-11.
• 5 Meroni PL. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of auto-immunity. J Autoimmun 2008; 30: 99-103.
• 6 Galli M, Reber G, de Moerloose P. et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399-401.
• 7 Galli M, Luciani D, Bertolini G. et al. Anti-beta 2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
• 8 Horbach DA, van Oort E, Donders RC. et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924.
• 9 Wahl DG, Guillemin F, de Maistre E. et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22.
• 10 Tubach F, Hayem G, Marchand JL. et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27: 1437-1443.
• 11 Galli M, Luciani D, Bertolini G. et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
• 12 Bas de Laat H, Derksen RH, Urbanus RT. et al. β₂-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-3602.
• 13 Zoghlami-Rintelen C, Vormittag R, Sailer T. et al. The presence of IgG antibodies against beta2-glyco-protein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-1165.
• 14 Pengo V, Biasolo A, Pegoraro C. et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
• 15 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Stan-dardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
• 16 Pengo V, Biasiolo A, Rampazzo P. et al. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein 1 autoantibodies. Thromb Haemost 1999; 81: 256-258.
• 17 Galli M, Finazzi G, Norbis F. et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81: 695-700.
• 18 Le Querrec A, Arnout J, Arnoux D. et al. Quantification of lupus anticoagulants in clinical samples using anti-β₂GP1 and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001; 86: 584-589.
• 19 Kandiah DA, Krilis SA. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in patients with the ‘antiphospholipid’ syndrome: immunological specificity and clotting profiles. Lupus 1998; 7: 323-332.
• 20 Horbach DA, van Oort E, Derksen RH. et al. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity – discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79: 790-795.
• 21 Goudemand J, Caron C, De Prost D. et al. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Société Française de Biologie Clinique and for the Groupe d’Études sur I’Hemostase et la Throm-bose. Thromb Haemost 1997; 77: 336-342.
• 22 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
• 23 De Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies – from clinical association to pathologic mechanism. Nature Clinical Practice 2008; 4: 192-199.
• 24 Oosting JD, Derksen RH, Entjes HT. et al. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein 1. Thromb Haemost 1992; 67: 499-502.
• 25 McNeil HP, Simpson RJ, Chesterman CN. et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
• 26 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
• 27 Matsuura E, Igarashi Y, Fujimoto M. et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178.
• 28 Pengo V, Biasiolo A, Pegoraro C. et al. A two-step coagulation test to identify anti-β₂-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-707.
• 29 Forasterio R, Martinuzzo M, Pombo G. et al. A prospective study of antibodies to β₂-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
• 30 Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048-1049.